Association between the sEH rs751141 polymorphism and the risk of ischemic stroke and hypertension: A systematic review and meta-analysis

To systematically evaluate the association between the rs751141 polymorphism in soluble epoxide hydrolase (sEH) and the risk of ischemic stroke and hypertension. We searched PubMed, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Chongqing VIP for eligible studies published through March 2024. Studies were selected based on inclusion and exclusion criteria. The quality of included studies was assessed using the Newcastle–Ottawa Scale (NOS) and Joanna Briggs Institute (JBI) tools. Data extraction and meta-analysis were performed using STATA software version 12. Twelve case-control studies were included, seven investigating the association of sEH rs751141 polymorphism with ischemic stroke risk, and five examining its association with hypertension risk. The pooled odds ratios (OR) and 95% confidence intervals for the allelic, dominant, and recessive models of ischemic stroke risk were 1.167 (1.045–1.303, p = 0.006), 1.381 (1.104–1.883, p = 0.041), and 0.856 (0.753–0.9751, p = 0.019), respectively. For hypertension risk, the pooled OR values and 95% confidence intervals were 1.343 (1.229–1.467, p < 0.001), 1.537 (1.254–1.885, p < 0.001), and 0.715 (0.64-0.80, p < 0.001), respectively. Carriers of the G allele of the sEH rs751141 polymorphism are at an increased risk for ischemic stroke and hypertension, while the A allele appears to have a protective effect against these conditions.